Epipole develops retinal imaging solutions, including handheld devices that take video scans of patients' retinas for assessment and diagnosis. Its flagship product is the video retinal imaging device, the epiCam. The company plans to use new funding to expand into the US market and to hire staff to support product launches and early commercialisation. Target clinical customers for commercialisation include primary care optometry and general ophthalmology practices. Epipole has undergone recent leadership change, appointing medtech executive Conal Harte as CEO while founder Craig Robertson moves to chief technology officer. Financially, the company recently secured fresh investment of £1.3 million and previously raised £1.5 million in June 2020 to support US market entry. Epipole, founded in 2011 and based in Scotland, created a patented technology that captures real-time video of the retina and extracts high-quality still images for clinical examination. Its core product is a portable, lower-cost alternative to large desktop retinal cameras. The company positions the device for easy use in primary care optometry and ophthalmology settings. Epipole has worked with ophthalmologists to test and refine features and capabilities. It plans to use the recent funding to implement key product changes and accelerate commercial rollout. The company announced a target of having product available by early 2021 and appointed Ian Stevens as chairman to support market introduction.

Total raised

$4M

Funding rounds

2

Latest round

Equity

Latest activity

Jan 2022